聚焦上皮-间质转化的转录因子生物标志物与靶向治疗的最新进展
Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial-Mesenchymal Transition.
作者信息
Chuang Kai-Ting, Chiou Shyh-Shin, Hsu Shih-Hsien
机构信息
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
出版信息
Cancers (Basel). 2023 Jun 25;15(13):3338. doi: 10.3390/cancers15133338.
Abstract
Transcription factors involve many proteins in the process of transactivating or transcribing (none-) encoded DNA to initiate and regulate downstream signals, such as RNA polymerase. Their unique characteristic is that they possess specific domains that bind to specific DNA element sequences called enhancer or promoter sequences. Epithelial-mesenchymal transition (EMT) is involved in cancer progression. Many dysregulated transcription factors-such as Myc, SNAIs, Twists, and ZEBs-are key drivers of tumor metastasis through EMT regulation. This review summarizes currently available evidence related to the oncogenic role of classified transcription factors in EMT editing and epigenetic regulation, clarifying the roles of the classified conserved transcription factor family involved in the EMT and how these factors could be used as therapeutic targets in future investigations.
摘要
转录因子在将（非）编码DNA反式激活或转录以启动和调节下游信号（如RNA聚合酶）的过程中涉及多种蛋白质。它们的独特特征是拥有与称为增强子或启动子序列的特定DNA元件序列结合的特定结构域。上皮-间质转化（EMT）与癌症进展有关。许多失调的转录因子，如Myc、SNAI、Twist和ZEB，是通过EMT调节促进肿瘤转移的关键驱动因素。本综述总结了目前与分类转录因子在EMT编辑和表观遗传调控中的致癌作用相关的证据，阐明了参与EMT的分类保守转录因子家族的作用，以及这些因子在未来研究中如何用作治疗靶点。
相似文献
1
Recent Advances in Transcription Factors Biomarkers and Targeted Therapies Focusing on Epithelial-Mesenchymal Transition.
Cancers (Basel). 2023 Jun 25;15(13):3338. doi: 10.3390/cancers15133338.
2
Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms.
Cell Prolif. 2023 Jun;56(6):e13423. doi: 10.1111/cpr.13423. Epub 2023 Feb 19.
3
Proteomics analysis reveals the role of ubiquitin specific protease (USP47) in Epithelial to Mesenchymal Transition (EMT) induced by TGFβ2 in breast cells.
J Proteomics. 2020 May 15;219:103734. doi: 10.1016/j.jprot.2020.103734. Epub 2020 Mar 19.
4
The novel role of Yin Yang 1 in the regulation of epithelial to mesenchymal transition in cancer via the dysregulated NF-κB/Snail/YY1/RKIP/PTEN Circuitry.
Crit Rev Oncog. 2011;16(3-4):211-26. doi: 10.1615/critrevoncog.v16.i3-4.50.
5
Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer.
Front Pharmacol. 2020 Nov 27;11:596239. doi: 10.3389/fphar.2020.596239. eCollection 2020.
6
Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions.
J Hematol Oncol. 2014 Mar 5;7:19. doi: 10.1186/1756-8722-7-19.
7
Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention.
Phys Biol. 2019 May 7;16(4):041004. doi: 10.1088/1478-3975/ab157a.
8
Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds.
Med Res Rev. 2023 Jul;43(4):1141-1200. doi: 10.1002/med.21948. Epub 2023 Mar 17.
9
Communication Between Epithelial-Mesenchymal Plasticity and Cancer Stem Cells: New Insights Into Cancer Progression.
Front Oncol. 2021 Apr 21;11:617597. doi: 10.3389/fonc.2021.617597. eCollection 2021.
10
Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives.
Cancer Manag Res. 2014 Apr 25;6:205-16. doi: 10.2147/CMAR.S38156. eCollection 2014.
引用本文的文献
1
Dextromethorphan Enhances Apoptosis and Suppresses EMT in PANC-1 Pancreatic Cancer Cells: Synergistic Effects with Gemcitabine.
Int J Mol Sci. 2025 Aug 22;26(17):8151. doi: 10.3390/ijms26178151.
2
Role of Androgen Receptor in Melanoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic Implications.
Cancers (Basel). 2025 Aug 29;17(17):2828. doi: 10.3390/cancers17172828.
3
Epithelial-Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications.
MedComm (2020). 2025 Aug 29;6(9):e70333. doi: 10.1002/mco2.70333. eCollection 2025 Sep.
4
Interleukin-6 Is a Crucial Factor in Shaping the Inflammatory Tumor Microenvironment in Ovarian Cancer and Determining Its Hot or Cold Nature with Diagnostic and Prognostic Utilities.
Cancers (Basel). 2025 May 17;17(10):1691. doi: 10.3390/cancers17101691.
5
The SOX gene superfamily in oncogenesis: unraveling links to ncRNAs, key pathways, chemoresistance, and gene editing approaches.
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 20. doi: 10.1007/s00210-025-04229-1.
6
Molecular Mechanisms Regulating Epithelial Mesenchymal Transition (EMT) to Promote Cancer Progression.
Int J Mol Sci. 2025 May 3;26(9):4364. doi: 10.3390/ijms26094364.
7
Heterozygous Tcf4 Deficiency Mitigates Fuchs Endothelial Corneal Dystrophy Progression in a Mouse Model.
Invest Ophthalmol Vis Sci. 2025 Apr 1;66(4):19. doi: 10.1167/iovs.66.4.19.
8
PIAS family gene expression: implications for prognosis, immunomodulation, and chemotherapy response.
Am J Transl Res. 2024 Nov 15;16(11):6346-6364. doi: 10.62347/JRDP4018. eCollection 2024.
9
Aryl hydrocarbon receptor dynamics in esophageal squamous cell carcinoma: From immune modulation to therapeutic opportunities.
World J Exp Med. 2024 Sep 20;14(3):96269. doi: 10.5493/wjem.v14.i3.96269.
10
Regulation of cellular and molecular markers of epithelial-mesenchymal transition by Brazilin in breast cancer cells.
PeerJ. 2024 May 9;12:e17360. doi: 10.7717/peerj.17360. eCollection 2024.
本文引用的文献
1
Trichostatin A inhibits expression of the human SLC2A5 gene via SNAI1/SNAI2 transcription factors and sensitizes colon cancer cells to platinum compounds.
Eur J Pharmacol. 2023 Jun 15;949:175728. doi: 10.1016/j.ejphar.2023.175728. Epub 2023 Apr 14.
2
Targeting the Retinoic Acid Pathway to Eradicate Cancer Stem Cells.
Int J Mol Sci. 2023 Jan 25;24(3):2373. doi: 10.3390/ijms24032373.
3
Dysregulated RUNX1 Predicts Poor Prognosis by Mediating Epithelialmesenchymal Transition in Cervical Cancer.
Curr Med Sci. 2022 Dec;42(6):1285-1296. doi: 10.1007/s11596-022-2661-x. Epub 2022 Dec 22.
4
Post-Translational Modification of ZEB Family Members in Cancer Progression.
Int J Mol Sci. 2022 Dec 1;23(23):15127. doi: 10.3390/ijms232315127.
5
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States.
Cancer Res. 2023 Jan 18;83(2):264-284. doi: 10.1158/0008-5472.CAN-22-0423.
6
Iron in Cancer Progression: Does BACH1 Promote Metastasis by Altering Iron Homeostasis?
Subcell Biochem. 2022;100:67-80. doi: 10.1007/978-3-031-07634-3_2.
7
Drugging p53 in cancer: one protein, many targets.
Nat Rev Drug Discov. 2023 Feb;22(2):127-144. doi: 10.1038/s41573-022-00571-8. Epub 2022 Oct 10.
8
BACH1 promotes clear cell renal cell carcinoma progression by upregulating oxidative stress-related tumorigenicity.
Cancer Sci. 2023 Feb;114(2):436-448. doi: 10.1111/cas.15607. Epub 2022 Nov 1.
9
The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.
J Hematol Oncol. 2022 Sep 8;15(1):129. doi: 10.1186/s13045-022-01347-8.
10
Role of estrogen receptors in health and disease.
Front Endocrinol (Lausanne). 2022 Aug 18;13:839005. doi: 10.3389/fendo.2022.839005. eCollection 2022.
Zotero 插件